Drug delivery system for the clinical application of cytokines

将重组人LT包封于免疫脂质体中，并偶联抗A375单克隆抗体。这些免疫脂质体在体外实验和体内实验中显示出对A375细胞的更强的类细胞作用。当将小鼠IFN-γ与人LT一起包封在抗A375缀合的免疫脂质体中，并且从A375细胞植入后2天开始每周两次将这些免疫脂质体给予裸鼠时，与使用仅包封人LT的免疫脂质体的实验相比，观察到显著更强的细胞毒性。这些结果清楚地表明，LT-免疫脂质体的至少一部分细胞毒性是通过宿主动物的免疫系统发挥的。

Recombinant human LT was encapsulated into immunoliposomes on which monoclonal anti-A375 antibody was conjugated. These immunoliposomes showed stronger cytotoidcity toward A375 cells in in vitro experiments and also in vivo experiments. When mouse IFN-Y was encapsulated in anti-A375-conjugated immunoliposomes together with human LT and those immunoliposomes were administered into nude mice twice a week starting from 2 days after implantation of A375 cells, significantly stronger cytotoxicity was observed compared with the experiments using immunoliposomes in which only human LT was encapsulated. These results clearly indicated that at least a part of cytotoxicity of LT-immunoliposomes was exerted through the immune system of host animals.